tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

INTS Stock Latest News

Intensity Therapeutics announces first dosing in Phase 2 trial of INT230-6
The FlyIntensity Therapeutics announces first dosing in Phase 2 trial of INT230-6
5d ago
INTS
Intensity Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Intensity Therapeutics initiated with a Buy at H.C. Wainwright
5d ago
INTS
Intensity Therapeutics Shareholders Engage and Elect at Annual Meeting
PremiumCompany Announcements
Intensity Therapeutics Shareholders Engage and Elect at Annual Meeting
4M ago
8K
INTS
Intensity Therapeutics doses first patient in Phase 3 sarcome study
PremiumThe Fly
Intensity Therapeutics doses first patient in Phase 3 sarcome study
4M ago
INTS
Intensity Therapeutics files to sell 394.5K shares of common stock for holders
PremiumThe Fly
Intensity Therapeutics files to sell 394.5K shares of common stock for holders
4M ago
INTS
Intensity Therapeutics files $150M mixed securities shelf
PremiumThe FlyIntensity Therapeutics files $150M mixed securities shelf
4M ago
INTS
Intensity Therapeutics Expands Board, Welcomes New Audit Director
Premium
Company Announcements
Intensity Therapeutics Expands Board, Welcomes New Audit Director
6M ago
8K
INTS
Intensity Therapeutics, The Swiss Group sign collaboration agreement
Premium
The Fly
Intensity Therapeutics, The Swiss Group sign collaboration agreement
6M ago
INTS
Intensity Therapeutics reports Q1 EPS (34c) vs. (39c) last year
PremiumThe Fly
Intensity Therapeutics reports Q1 EPS (34c) vs. (39c) last year
6M ago
INTS
Portage Biotech completes monetization of Intensity Therapeutics shares
PremiumThe Fly
Portage Biotech completes monetization of Intensity Therapeutics shares
7M ago
INTS
PRTG
Intensity Therapeutics says cash sufficient to fund operations through 1Q25
PremiumThe Fly
Intensity Therapeutics says cash sufficient to fund operations through 1Q25
8M ago
INTS
Intensity Therapeutics Unveils New Incentive Compensation Plan
PremiumCompany Announcements
Intensity Therapeutics Unveils New Incentive Compensation Plan
9M ago
8K
INTS
Intensity Therapeutics, Inc. trading resumes
PremiumThe FlyIntensity Therapeutics, Inc. trading resumes
11M ago
INTS
Intensity Therapeutics, Inc. trading halted, volatility trading pause
Premium
The Fly
Intensity Therapeutics, Inc. trading halted, volatility trading pause
11M ago
INTS
Intensity Therapeutics names Joseph Talamo as CFO
Premium
The Fly
Intensity Therapeutics names Joseph Talamo as CFO
11M ago
INTS
Intensity Therapeutics reports results from Phase 2 INVINCIBLE trial of INT230-6
PremiumThe Fly
Intensity Therapeutics reports results from Phase 2 INVINCIBLE trial of INT230-6
11M ago
INTS
Intensity Therapeutics reports Q3 EPS (17c) vs (52c) last year
PremiumThe Fly
Intensity Therapeutics reports Q3 EPS (17c) vs (52c) last year
12M ago
INTS
Intensity Therapeutics presents INT230-6 data at CTOSAM 2023
PremiumThe Fly
Intensity Therapeutics presents INT230-6 data at CTOSAM 2023
1y ago
INTS
Intensity receives Orphan Drug Designation for three ingredients in INT230-6
PremiumThe Fly
Intensity receives Orphan Drug Designation for three ingredients in INT230-6
1y ago
INTS
Opening Day: Beauty brand owner Oddity soars in debut
PremiumThe FlyOpening Day: Beauty brand owner Oddity soars in debut
1y ago
KGS
NIO
Intensity Therapeutics initiated with a Speculative Buy at Benchmark
Premium
The Fly
Intensity Therapeutics initiated with a Speculative Buy at Benchmark
1y ago
INTS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >